Column

Editor's Page

Utilizing Pathways Among Shifting Market Dynamics

02/15/2018

Winston Wong, PharmD, Editor-in-Chief

As the health care system collectively progresses toward full adoption of the Medicare Access and CHIP reauthorization Act, providers, practices, and health systems have been working to understand the full impact of...

As the...

02/15/2018

Journal of Clinical Pathways

Pathways in Focus

Heuristics Matter: The Principle Reason Why Clinical Pathways Fall Short on Capturing Value

12/13/2017

Aymen Elfiky, MD, MSc, MBA—Column Editor

12/13/2017

Journal of Clinical Pathways

Clinical Pathways GPS

How New Rules for 2018 Will Impact Clinical Pathways

12/13/2017

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

12/13/2017

Journal of Clinical Pathways

Pharma Insights

The Influence of Europe on the Pricing, Uptake, and Overall Impact of Biosimilars

12/13/2017

Kellie Rademacher, PharmD

Todd Edgar, PharmD, MS

12/13/2017

Journal of Clinical Pathways

Editor's Page

Clinical Pathways for 2018 and Beyond

12/13/2017

Winston Wong, PharmD, Editor-in-Chief

As another year draws to a close, I look back on the work produced by Journal of Clinical Pathways (JCP) with pride. But it is still important to keep our focus on what’s next. I have no doubt that 2018 will bring...

As...

12/13/2017

Journal of Clinical Pathways

Clinical Pathways GPS

Atypical Players in the Treatment Landscape

11/27/2017

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

CVS pharmacy recently made an offer to acquire Aetna Health Plan for $66 billion.1 This is a true game changer for two reasons: first, it represents the most significant national integration of service provider and...

CVS...

11/27/2017

Journal of Clinical Pathways

Editor's Page

Mergers and Acquisitions in Clinical Pathways

11/27/2017

Winston Wong, PharmD, Editor-in-Chief

This time of year brings about holidays, time with family, and time for reflection as we move into a new calendar cycle. For those of us who work in medicine—no matter the specialty or area—it can also be a time for...

This...

11/27/2017

Journal of Clinical Pathways

Editor's Page

Integrating Gene Therapy Into Value-Based Care

10/16/2017

Winston Wong, PharmD, Editor-in-Chief

Medical advances emerge swiftly, and sometimes surprisingly. The rapid number of new products approved by the Food and Drug Administration (FDA) for the treatment and care of patients with cancer perfectly...

...

10/16/2017

Journal of Clinical Pathways

Clinical Pathways GPS

Looking for Leadership in Developing Pathways

10/16/2017

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Scott Guerin, PhD

A clinical pathway can be defined as an “optimal sequencing and timing of interventions by physicians, nurses, and other staff for a particular diagnosis or procedure.” As organizations new to pathways look to...

A...

10/16/2017

Journal of Clinical Pathways

Pharma Insights

Orphan Drugs: Understanding the Payer Perspective

10/16/2017

Kellie Rademacher, PharmD

Hetty A Lima, BSPharm, RPh, FASHP

New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. The passage of the Orphan Drug...

New...

10/16/2017

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products